Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Edesa Biotech (EDSA) Operating Expenses (2016 - 2022)

Edesa Biotech's Operating Expenses history spans 10 years, with the latest figure at $2.8 million for Q3 2022.

  • For Q3 2022, Operating Expenses fell 48.29% year-over-year to $2.8 million; the TTM value through Sep 2022 reached $18.4 million, down 22.43%, while the annual FY2025 figure was $7.9 million, 12.78% up from the prior year.
  • Operating Expenses for Q3 2022 was $2.8 million at Edesa Biotech, down from $5.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $9.5 million in Q1 2021 and bottomed at $405741.0 in Q4 2018.
  • The 5-year median for Operating Expenses is $2.2 million (2020), against an average of $3.1 million.
  • The largest annual shift saw Operating Expenses tumbled 71.23% in 2018 before it surged 1791.44% in 2021.
  • A 5-year view of Operating Expenses shows it stood at $405741.0 in 2018, then surged by 199.08% to $1.2 million in 2019, then surged by 115.4% to $2.6 million in 2020, then skyrocketed by 97.48% to $5.2 million in 2021, then plummeted by 45.05% to $2.8 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Operating Expenses are $2.8 million (Q3 2022), $5.8 million (Q2 2022), and $4.6 million (Q1 2022).